Quarterly report (Form 10-Q)
Edwards Lifesciences 10-Q for Quarter ended Mar 31, 2026
Filing excerpt
Gross profit as a percentage of net sales decreased for the three months ended March 31, 2026, primarily driven by a 0.3 percentage point negative impact from foreign currency rate fluctuations, including the settlement of foreign currency hedging contracts, and additional manufacturing expenses related to expansion of new therapies.